Meta will begin using data from AI chatbot conversations and other AI-powered products to fuel targeted advertising across Facebook and Instagram, with no way to opt out. The policy change, effective December 16, excludes users in South Korea, the UK, and the EU due to stricter privacy laws. TechCrunch reports: If a user chats with Meta AI about hiking, for example, the company may show ads for hiking gear. However, Meta spokesperson Emil Vazquez tells TechCrunch that the privacy update is broader than just Meta AI and applies to the company's other AI offerings. That means Meta may use data from AI features in its Ray-Ban Meta smart glasses -- including voice recordings, pictures, and videos analyzed with AI -- to further target its ad products. Meta may also use data from its new AI-video feed, Vibes, and its AI image generation product, Imagine. Conversations with Meta AI will only influence ads on Facebook and Instagram if a user is logged into the same account across products. [...] Meta says the company has "no plans imminently" to put ads in its AI products, though CEO Mark Zuckerberg has suggested they may be coming in the future.

Read more of this story at Slashdot.

President Trump on Tuesday issued a memorandum directing the FDA and HHS to crack down on misleading direct-to-consumer prescription drug ads, requiring clearer disclosure of risks and ensuring that promotions don't overstate benefits or push costly drugs over generics. Longtime Slashdot reader sinij shares an excerpt from the memorandum: The Secretary of Health and Human Services shall therefore take appropriate action to ensure transparency and accuracy in direct-to-consumer prescription drug advertising, including by increasing the amount of information regarding any risks associated with the use of any such prescription drug required to be provided in prescription drug advertisements, to the extent permitted by applicable law. The Commissioner of Food and Drugs shall take appropriate action to enforce the Federal Food, Drug, and Cosmetic Act's prescription drug advertising provisions, and otherwise ensure truthful and non-misleading information in direct-to-consumer prescription drug advertisements. "Advertising dollars is a major avenue for pharmaceutical companies to influence news and attempt to shape public opinion," comments sinij. "Advertising was a major contributor to painkiller addiction, where networks were hesitant to cover early reports of addictiveness. It is likely directly contributing today to lack of critical coverage of Ozempic. It is just too big of a conflict of interest to allow to stand."

Read more of this story at Slashdot.

An anonymous reader quotes a report from TechCrunch: Amazon CEO Andy Jassy sees an opportunity to deliver ads to users during their conversations with the company's AI-powered digital assistant, Alexa+, he said during Amazon's second-quarter earnings call Thursday. "People are excited about the devices that they can buy from us that has Alexa+ enabled in it. People do a lot of shopping [with Alexa+]; it's a delightful shopping experience that will keep getting better," said Jassy on the call with investors and Wall Street analysts. "I think over time, there will be opportunities, as people are engaging in more multi-turn conversations, to have advertising play a role to help people find discovery, and also as a lever to drive revenue." [...] Amazon has made Alexa+ free for Prime customers (who pay $14.99 a month) and added a $20-a-month subscription tier for Alexa+ on its own. Jassy suggested on Thursday that Alexa+ could eventually include subscription tiers beyond what's available today -- perhaps an ad-free tier. Up until now, ads have only appeared in Alexa in limited ways. Users may occasionally see a visual ad on Amazon's smart display device, the Echo Show, or hear a pre-recorded ad in between songs on one of Alexa's smart speakers. But Jassy's description of an AI-generated ad that Alexa+ delivers in a multistep conversation, which could help users find new products, is uncharted territory for Amazon and the broader tech industry. Marketers have expressed interest in advertising in AI chatbots, and specifically Alexa+, but exactly how remains unclear. [...] Jassy is betting that users will talk to Alexa+ more than Alexa, which could drive more advertising and more shopping on Amazon.com. However, early reviews of Alexa+ have been mixed. Amazon has reportedly struggled to ship some of Alexa+'s more complicated features, and the rollout has been slower than many expected. There's a lot to figure out before Amazon puts ads in Alexa+. Like most AI models, Alexa+ is not immune to hallucinations. Before advertisers agree to make Alexa+ a spokesperson for their products, Amazon may have to come up with some ways to ensure that its AI will not offer false advertising for a product. Jassy seems enthusiastic about making advertising a larger part of Amazon business. Amazon's advertising revenue went up 22% in the second quarter, compared to the same period last year. Delivering ads in AI chatbot conversations may also raise privacy concerns. People tend to talk more with AI chatbots compared to deterministic assistants, like the traditional Alexa and Siri products. As a result, generative AI chatbots tend to collect more information on users. Some users might be unsettled by having that information sold to advertisers and having ads appear in their natural language conversations with AI.

Read more of this story at Slashdot.